Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.

Also called NCT03212365

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose other
Phase
Phase 2
Enrolled
  • 295 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03212365
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03212365. Randomized; double masking; primary purpose other. Start 2017-07-03 (actual); primary completion 2019-06-02 (actual). Results posted on 2020-09-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Condition
Venous Thromboembolism
Condition
Deep Venous Thrombosis
Condition
Pulmonary Embolus
Condition
Reconstructive Surgery
Intervention (Drug)
Fixed dose
Intervention (Drug)
Variable dose
Lead sponsor
University of Utah (class: other)
Collaborator
Stanford University (class: other)

Record details

Record id
cardio:ct-nct03212365
Content hash
0534dc8f167fa35636b08a4de39d8d510aea45176a9649964f39edefb5e1e6e4